Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment...
Uloženo v:
| Vydáno v: | British journal of ophthalmology Ročník 106; číslo 3; s. 297 - 304 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
BMA House, Tavistock Square, London, WC1H 9JR
BMJ Publishing Group Ltd
01.03.2022
BMJ Publishing Group LTD BMJ Publishing Group |
| Témata: | |
| ISSN: | 0007-1161, 1468-2079, 1468-2079 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis—something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD. |
|---|---|
| AbstractList | Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis—something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD. Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD.Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD. |
| Author | Georgiou, Michalis Cabral de Guimaraes, Thales Antonio Daich Varela, Malena Michaelides, Michel |
| AuthorAffiliation | 2 Moorfields Eye Hospital NHS Foundation Trust , London , London , UK 1 Institute of Ophthalmology , University College London , London , London , UK |
| AuthorAffiliation_xml | – name: 1 Institute of Ophthalmology , University College London , London , London , UK – name: 2 Moorfields Eye Hospital NHS Foundation Trust , London , London , UK |
| Author_xml | – sequence: 1 givenname: Thales Antonio orcidid: 0000-0002-7936-6851 surname: Cabral de Guimaraes fullname: Cabral de Guimaraes, Thales Antonio organization: Moorfields Eye Hospital NHS Foundation Trust, London, London, UK – sequence: 2 givenname: Malena orcidid: 0000-0003-4960-4510 surname: Daich Varela fullname: Daich Varela, Malena organization: Moorfields Eye Hospital NHS Foundation Trust, London, London, UK – sequence: 3 givenname: Michalis orcidid: 0000-0001-6397-8071 surname: Georgiou fullname: Georgiou, Michalis organization: Moorfields Eye Hospital NHS Foundation Trust, London, London, UK – sequence: 4 givenname: Michel surname: Michaelides fullname: Michaelides, Michel email: michel.michaelides@ucl.ac.uk organization: Moorfields Eye Hospital NHS Foundation Trust, London, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33741584$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUctuFDEQtFAQ2QR-AVniwoEBv8bj4YCEogSQInEJZ8vj6dn1ymMvtidS_h4vmxe5ACfb3V3lqq4TdBRiAIQwJe8p5fLDsI27TdkYP0ffMMJIw6kSLXuGVlRIVUtdf4RWhJCuoVTSY3SS87Y-maTdC3TMeSdoq8QKxasEpswQSsZTTHhMN9isoUngTYERz8Yu3tQ6rCFAMsXF8BGXTb3uYCnOYnMNYYH8DlvvgrPG45Kc8RmbMOJpKUsCPLoEdg_NL9HzqTbh1e15in5cnF-dfW0uv3_5dvb5shkk4aWhHcheqVFQmHrS9rIzBIRqp4ECY4y3BCgZOykn0kM79JzISVoFlDGYrBz5Kfp04N0twwyjrQaT8XqX3GzSjY7G6T87wW30Ol5rpWRXt1QJ3t4SpPiz-it6dtmC9yZAXLJmLeFCKE5EHX3zZHQblxSqPc3kfqDr-Z7w9WNF91LusniQbFPMOcGkrSu_F14FOq8p0fvw9ePw9T58fQi_EqgnBHd__AOUH6DDvP0flHhA3Xv-K-wXlF7dIA |
| CitedBy_id | crossref_primary_10_1021_cbe_5c00059 crossref_primary_10_1016_j_coph_2024_102439 crossref_primary_10_1016_j_exer_2024_109889 crossref_primary_10_1007_s00018_022_04670_y crossref_primary_10_3390_ijms25126404 crossref_primary_10_1186_s12575_024_00248_z crossref_primary_10_1038_s41418_022_00967_4 crossref_primary_10_1016_j_oret_2022_05_002 crossref_primary_10_3390_jcm13133959 crossref_primary_10_1177_15353702231181188 crossref_primary_10_14309_ctg_0000000000000802 crossref_primary_10_1021_jacs_3c06898 crossref_primary_10_3390_pharmaceutics15030837 crossref_primary_10_1002_advs_202503212 crossref_primary_10_1186_s13062_025_00648_5 crossref_primary_10_3390_cells12071071 crossref_primary_10_1016_j_exer_2023_109770 crossref_primary_10_2217_imt_2022_0263 crossref_primary_10_3390_jcm12144862 crossref_primary_10_1016_j_addr_2023_115005 crossref_primary_10_1080_17425247_2025_2482049 crossref_primary_10_1016_j_exer_2025_110632 crossref_primary_10_1186_s41065_024_00356_6 crossref_primary_10_3892_ijmm_2024_5400 crossref_primary_10_3390_ijms232112982 crossref_primary_10_1093_hmg_ddab256 crossref_primary_10_3390_ijms252111850 crossref_primary_10_1016_j_jpha_2025_101285 crossref_primary_10_1177_13591053231204722 crossref_primary_10_1016_j_biopha_2024_116424 crossref_primary_10_7759_cureus_41615 crossref_primary_10_1007_s00717_024_00578_z crossref_primary_10_3389_fimmu_2023_1107295 crossref_primary_10_3390_life14091189 crossref_primary_10_1016_j_ophtha_2024_11_017 crossref_primary_10_3390_antiox12061211 crossref_primary_10_1016_j_carbon_2022_09_045 crossref_primary_10_1097_IAE_0000000000004209 crossref_primary_10_3390_genes13071233 crossref_primary_10_1136_bmjophth_2023_001525 crossref_primary_10_3389_fphar_2021_798938 crossref_primary_10_1016_j_omtn_2024_102195 crossref_primary_10_1016_j_pharmthera_2025_108862 crossref_primary_10_1002_mnfr_70199 crossref_primary_10_1007_s00417_024_06399_9 crossref_primary_10_1159_000538696 crossref_primary_10_1097_st9_0000000000000001 crossref_primary_10_3390_ph16040620 crossref_primary_10_1016_j_bbrc_2025_151857 crossref_primary_10_1016_j_oret_2022_08_003 crossref_primary_10_1038_s41419_022_05121_z crossref_primary_10_1080_14728222_2022_2157260 crossref_primary_10_1097_ICB_0000000000001488 crossref_primary_10_1080_15548627_2023_2220540 crossref_primary_10_1007_s10792_021_02170_9 crossref_primary_10_3390_biomedicines10081884 crossref_primary_10_3390_ijms24108763 crossref_primary_10_1186_s13287_022_02894_0 crossref_primary_10_3390_ijms252111357 crossref_primary_10_1016_j_addr_2022_114342 crossref_primary_10_1038_s41598_025_07299_6 crossref_primary_10_1016_j_preteyeres_2025_101360 crossref_primary_10_1007_s13346_024_01772_x crossref_primary_10_1016_S0140_6736_22_02609_5 crossref_primary_10_3390_life11070635 crossref_primary_10_7759_cureus_29583 crossref_primary_10_1016_j_heliyon_2023_e22307 crossref_primary_10_1007_s10792_023_02732_z crossref_primary_10_1186_s40246_024_00637_1 crossref_primary_10_3390_antiox12071379 crossref_primary_10_1080_09638288_2025_2493213 crossref_primary_10_1016_j_oret_2022_05_030 crossref_primary_10_1007_s00417_024_06418_9 crossref_primary_10_1016_j_cclet_2025_111714 crossref_primary_10_3390_biomedicines13071552 crossref_primary_10_3390_cells14090633 crossref_primary_10_3390_diagnostics13010130 crossref_primary_10_3390_metabo13020187 crossref_primary_10_1016_j_exer_2024_109823 crossref_primary_10_1177_24741264231210078 crossref_primary_10_3389_fphar_2022_1038730 crossref_primary_10_1016_j_jep_2024_118565 crossref_primary_10_1038_s41597_024_03844_6 crossref_primary_10_1080_17425247_2022_2017878 crossref_primary_10_1002_jca_22043 crossref_primary_10_1186_s40942_023_00493_6 crossref_primary_10_1016_j_displa_2023_102391 crossref_primary_10_1111_jce_16627 crossref_primary_10_1016_j_ajcnut_2024_06_018 crossref_primary_10_1080_07853890_2023_2250538 crossref_primary_10_1111_aos_15275 crossref_primary_10_3389_fgene_2024_1391999 crossref_primary_10_1038_s41433_024_03341_5 crossref_primary_10_1039_D2BM00905F crossref_primary_10_3390_pharmaceutics15051416 crossref_primary_10_1016_j_exer_2024_110227 crossref_primary_10_14348_molcells_2023_2188 crossref_primary_10_1038_s41433_021_01725_5 crossref_primary_10_1002_adhm_202401613 crossref_primary_10_3389_fphar_2025_1543575 crossref_primary_10_3390_pharmaceutics13091376 crossref_primary_10_1016_j_drudis_2024_103920 crossref_primary_10_1002_ctm2_952 crossref_primary_10_1080_15257770_2025_2512853 crossref_primary_10_1007_s12015_024_10689_4 crossref_primary_10_1038_s41420_023_01695_5 crossref_primary_10_3389_fimmu_2023_1138519 crossref_primary_10_3390_pr10040678 crossref_primary_10_3390_life13020568 crossref_primary_10_3390_biom15070940 crossref_primary_10_1002_jbm_a_37736 crossref_primary_10_1167_iovs_63_6_6 |
| Cites_doi | 10.1155/2011/802059 10.1001/jamaophthalmol.2013.7376 10.1007/978-3-319-17121-0_57 10.1111/bph.12461 10.1016/j.ophtha.2017.09.028 10.1097/IAE.0000000000002789 10.1371/journal.pone.0019078 10.1016/j.neuropharm.2014.12.038 10.1016/j.ophtha.2013.09.044 10.1111/j.1471-4159.2010.07092.x 10.1016/s0002-9394(02)01624-0 10.1016/j.imbio.2019.05.003 10.1001/jama.2013.4997 10.1093/oxfordjournals.aje.a009421 10.1001/archophthalmol.2010.18 10.1002/path.4669 10.1016/j.ophtha.2012.10.036 10.1016/S0161-6420(91)32186-9 10.1002/humu.21256 10.1016/S2214-109X(17)30393-5 10.1016/j.ajo.2010.09.026 10.1016/j.neuropharm.2014.12.037 10.1016/j.ajo.2017.04.006 10.1002/14651858.CD000254.pub4 10.1089/jop.2007.0022 10.1093/ajcn/73.2.209 10.1016/j.exer.2010.04.012 10.1074/jbc.M112.345082 10.1074/jbc.M110.178657 10.1016/j.exer.2019.05.006 10.1016/S0041-1345(03)00356-7 10.1167/iovs.07-1012 10.1016/j.exer.2015.09.003 10.1097/IAE.0b013e318265801d 10.1016/j.preteyeres.2008.10.001 10.1136/bjophthalmol-2020-316195 10.1001/archopht.1996.01100140716016 10.1186/s12913-019-4666-0 10.1016/j.preteyeres.2011.11.005 10.3945/ajcn.2009.27594 10.1634/stemcells.2006-0308erratum 10.1016/j.exer.2011.06.015 10.1002/jgm.2865 10.1016/j.oret.2018.03.001 10.1016/S2214-109X(13)70145-1 10.1016/s0039-6257(05)80092-x 10.1167/iovs.13-11650 10.1167/iovs.12-9970 10.1002/path.4266 10.1001/jamaophthalmol.2018.1544 10.1016/j.ophtha.2019.07.011 10.1096/fj.14-262444 10.1124/jpet.114.215921 10.1016/j.ophtha.2018.09.015 10.1167/iovs.10-6476 10.1167/iovs.10-5637 10.1016/j.preteyeres.2017.03.002 10.1016/S0140-6736(14)61376-3 10.1016/j.ophtha.2018.03.059 10.1016/j.preteyeres.2008.11.004 10.1016/j.preteyeres.2018.02.002 10.1167/iovs.05-0820 10.1074/jbc.M110.178640 10.1056/NEJMoa061648 10.1016/j.exer.2015.07.007 10.2165/00019053-200826010-00006 10.1126/scitranslmed.aao4097 10.1038/ng.2578 10.1080/13543784.2020.1763953 10.1093/hmg/ddx228 10.1016/j.preteyeres.2014.11.005 10.1016/j.ophtha.2020.08.027 10.1073/pnas.0600236103 10.1016/S0039-6257(05)80092-X 10.1634/stemcells.2006-0308. 10.1016/S0002-9394(02)01624-0 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. 2022 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. – notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. – notice: 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. 2022 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1136/bjophthalmol-2020-318452 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-2079 |
| EndPage | 304 |
| ExternalDocumentID | PMC8867261 33741584 10_1136_bjophthalmol_2020_318452 bjophthalmol |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | United Kingdom--UK Australia United States--US |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US – name: Australia |
| GrantInformation_xml | – fundername: Retina UK grantid: None funderid: http://dx.doi.org/10.13039/501100000310 – fundername: Moorfields Eye Charity grantid: None – fundername: Wellcome Trust grantid: 099173/Z/12/Z funderid: http://dx.doi.org/10.13039/100004440 – fundername: Foundation Fighting Blindness grantid: None funderid: http://dx.doi.org/10.13039/501100000262 – fundername: Wellcome Trust grantid: 099173/Z/12/Z – fundername: Wellcome Trust – fundername: ; grantid: None – fundername: ; grantid: 099173/Z/12/Z |
| GroupedDBID | --- -~X .55 .GJ .VT 0R~ 18M 23N 2WC 354 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 8FI 8FJ 8R4 8R5 9YT AAHLL AAKAS AAOJX AAWJN ABAAH ABJNI ABKDF ABMQD ABTFR ABUWG ABVAJ ACCCW ACGFO ACGFS ACGTL ACHTP ACMFJ ACMMV ACNCT ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DU5 E3Z EBS EJD F5P FYUFA H13 HAJ HMCUK HYE HZ~ IAO IEA IHR IOF ITC J5H KQ8 L7B M1P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UAW UKHRP UYXKK V24 VM9 W8F WH7 WOQ X7M XOL YFH YQY ZGI AAFWJ AAYXX ACQHZ AERUA AFFHD CITATION PHGZM PJZUB PPXIY CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-b603t-17e6988d41ef905967a0e485fb1e222350e10d766f09e5b9306f6c8e122efc6d3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 143 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000726872800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0007-1161 1468-2079 |
| IngestDate | Tue Nov 04 01:59:38 EST 2025 Sun Nov 09 10:57:54 EST 2025 Tue Oct 07 07:12:24 EDT 2025 Mon Jul 21 05:18:33 EDT 2025 Sat Nov 29 03:06:08 EST 2025 Tue Nov 18 21:07:13 EST 2025 Thu Apr 24 22:50:47 EDT 2025 Thu Apr 24 22:49:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | genetics retina angiogenesis degeneration macula |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b603t-17e6988d41ef905967a0e485fb1e222350e10d766f09e5b9306f6c8e122efc6d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-6397-8071 0000-0002-7936-6851 0000-0003-4960-4510 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8867261 |
| PMID | 33741584 |
| PQID | 2630437931 |
| PQPubID | 2041039 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8867261 proquest_miscellaneous_2503448304 proquest_journals_2630437931 pubmed_primary_33741584 crossref_citationtrail_10_1136_bjophthalmol_2020_318452 crossref_primary_10_1136_bjophthalmol_2020_318452 bmj_primary_10_1136_bjophthalmol_2020_318452 bmj_journals_10_1136_bjophthalmol_2020_318452 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-01 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationPlace_xml | – name: BMA House, Tavistock Square, London, WC1H 9JR – name: England – name: London |
| PublicationTitle | British journal of ophthalmology |
| PublicationTitleAbbrev | Br J Ophthalmol |
| PublicationTitleAlternate | Br J Ophthalmol |
| PublicationYear | 2022 |
| Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Klein, Klein, Moss (R13) 1998; 147 Ding, Patel, Chan (R25) 2009; 28 (R28) 2013; 309 Cho, Hung, Willett (R12) 2001; 73 Sadda, Guymer, Holz (R8) 2018; 125 Mata, Lichter, Vogel (R41) 2013; 33 Evans, Lawrenson (R30) 2017; 7 Pardue, Allen (R65) 2018; 65 Bird, Bressler, Bressler (R7) 1995; 39 DeAngelis, Owen, Morrison (R10) 2017; 26 Merin, Obolensky, Farber (R69) 2008; 24 Cashman, Ramo, Kumar-Singh (R79) 2011; 6 Kumar-Singh (R78) 2019; 184 Rammes, Gravius, Ruitenberg (R33) 2015; 92 Chew, Clemons (R29) 2014; 132 Rosenfeld, Dugel, Holz (R39) 2018; 125 Wen, Tao, Li (R64) 2012; 31 Jobling, Guymer, Vessey (R91) 2015; 29 Mullins, Dewald, Streb (R24) 2011; 93 WoldeMussie, Ruiz, Wijono (R73) 2001; 42 Cousin, Saloupis, Brahmajoti (R89) 2016; 57 Mullins, Johnson, Faidley (R23) 2011; 52 Wong, Su, Li (R2) 2014; 2 Lachmann (R81) 2019; 224 Kim, Park, Byun (R4) 2019; 19 Camardo (R50) 2003; 35 Lawson, Bhatia, Han (R61) 2016; 854 Lund, Wang, Lu (R84) 2007; 25 Csaky, Westby, Rezaei (R53) 2020; 61 Guymer, Wu, Hodgson (R92) 2019; 126 Ma, Kaufman, Zhang (R42) 2011; 286 Cruess, Zlateva, Xu (R3) 2008; 26 Liao, Grossi, El Mehdi (R55) 2020; 127 Lafuente, Villegas-Pérez, Sobrado-Calvo (R70) 2001; 42 Ellis, Buchberger, Holder (R82) 2020; 61 Parsons, Ruitenberg, Freitag (R36) 2015; 92 Wong, Kam, Cunningham (R32) 2010; 51 Holz, Sadda, Busbee (R49) 2018; 136 Oveson, Iwase, Hackett (R60) 2011; 116 Yehoshua, de Amorim Garcia Filho, Nunes (R46) 2014; 121 Loyet, Good, Davancaze (R47) 2014; 351 Feigl (R16) 2009; 28 Schwartz, Regillo, Lam (R86) 2015; 385 Guimaraes, Georgiou, Bainbridge (R5) 2021; 105 Fritsche, Chen, Schu (R26) 2013; 45 Hillmen, Young, Schubert (R44) 2006; 355 Shibagaki, Okamoto, Katsuta (R63) 2015; 139 Sieving, Caruso, Tao (R66) 2006; 103 van Lookeren Campagne, LeCouter, Yaspan (R18) 2014; 232 Donello, Padillo, Webster (R71) 2001; 296 Rajagopalan, Ghosn, Tamhane (R74) 2019; 60 Whitmore, Sohn, Chirco (R22) 2015; 45 Krupin, Liebmann, Greenfield (R68) 2011; 151 Kashani, Lebkowski, Rahhal (R87) 2018; 10 Cashman, Gracias, Adhi (R83) 2015; 17 Anderson, Mullins, Hageman (R15) 2002; 134 Ferris, Wilkinson, Bird (R9) 2013; 120 Katschke, Wu, Ganesan (R48) 2012; 287 Datta, Cano, Ebrahimi (R11) 2017; 60 Wong, Dresner, Forooghian (R51) 2013; 54 Flaxman, Bourne, Resnikoff (R1) 2017; 5 Ebrahimi, Handa (R17) 2011; 2011 Shaw, Mackin, Shah (R58) 2020; 29 Szeto (R88) 2014; 171 Zeng, Whitmore, Sohn (R21) 2016; 238 Radu, Han, Bui (R40) 2005; 46 Sangiovanni, Agrón, Meleth (R27) 2009; 90 Ho, Chang, Samuel (R85) 2017; 179 Maga, Nishimura, Weaver (R45) 2010; 31 Kuppermann, Patel, Boyer (R75) 2021; 41 Kauper, McGovern, Sherman (R67) 2012; 53 Kaufman, Ma, Washington (R43) 2011; 286 Rosenfeld, Berger, Reichel (R34) 2018; 2 Klein, Davis, Magli (R6) 1991; 98 Gehrs, Jackson, Brown (R19) 2010; 128 Yoles, Wheeler, Schwartz (R72) 1999; 40 Smith, Mitchell, Leeder (R14) 1996; 114 Chirco, Tucker, Stone (R20) 2016; 146 Phillips, Walker, Choi (R62) 2008; 49 Tanito, Li, Anderson (R31) 2010; 91 Jaffe, Westby, Csaky (R52) 2020; S0161-6420 Whitmore, Sohn, Chirco 2015; 45 Anderson, Mullins, Hageman 2002; 134 Wong, Kam, Cunningham 2010; 51 Cousin, Saloupis, Brahmajoti 2016; 57 Pardue, Allen 2018; 65 Phillips, Walker, Choi 2008; 49 Krupin, Liebmann, Greenfield 2011; 151 Smith, Mitchell, Leeder 1996; 114 Ellis, Buchberger, Holder 2020; 61 Wen, Tao, Li 2012; 31 Maga, Nishimura, Weaver 2010; 31 Katschke, Wu, Ganesan 2012; 287 Yoles, Wheeler, Schwartz 1999; 40 Ho, Chang, Samuel 2017; 179 Tanito, Li, Anderson 2010; 91 Lachmann 2019; 224 Sieving, Caruso, Tao 2006; 103 Cashman, Gracias, Adhi 2015; 17 Guymer, Wu, Hodgson 2019; 126 Lafuente, Villegas-Pérez, Sobrado-Calvo 2001; 42 Guimaraes, Georgiou, Bainbridge 2021; 105 Cruess, Zlateva, Xu 2008; 26 Wong, Su, Li 2014; 2 Liao, Grossi, El Mehdi 2020; 127 Cashman, Ramo, Kumar-Singh 2011; 6 Mata, Lichter, Vogel 2013; 33 Ma, Kaufman, Zhang 2011; 286 Mullins, Johnson, Faidley 2011; 52 Klein, Klein, Moss 1998; 147 Bird, Bressler, Bressler 1995; 39 Parsons, Ruitenberg, Freitag 2015; 92 Evans, Lawrenson 2017; 7 Jaffe, Westby, Csaky 2020; S0161-6420 Yehoshua, de Amorim Garcia Filho, Nunes 2014; 121 Donello, Padillo, Webster 2001; 296 Flaxman, Bourne, Resnikoff 2017; 5 Ferris, Wilkinson, Bird 2013; 120 Rosenfeld, Dugel, Holz 2018; 125 Rajagopalan, Ghosn, Tamhane 2019; 60 Oveson, Iwase, Hackett 2011; 116 Lawson, Bhatia, Han 2016; 854 Rammes, Gravius, Ruitenberg 2015; 92 Shaw, Mackin, Shah 2020; 29 Gehrs, Jackson, Brown 2010; 128 Chew, Clemons 2014; 132 Lund, Wang, Lu 2007; 25 Rosenfeld, Berger, Reichel 2018; 2 Datta, Cano, Ebrahimi 2017; 60 Jobling, Guymer, Vessey 2015; 29 Camardo 2003; 35 2013; 309 Feigl 2009; 28 Ebrahimi, Handa 2011; 2011 Kim, Park, Byun 2019; 19 Kaufman, Ma, Washington 2011; 286 Loyet, Good, Davancaze 2014; 351 Merin, Obolensky, Farber 2008; 24 Radu, Han, Bui 2005; 46 DeAngelis, Owen, Morrison 2017; 26 Klein, Davis, Magli 1991; 98 Csaky, Westby, Rezaei 2020; 61 Chirco, Tucker, Stone 2016; 146 Kuppermann, Patel, Boyer 2021; 41 Cho, Hung, Willett 2001; 73 Mullins, Dewald, Streb 2011; 93 Sangiovanni, Agrón, Meleth 2009; 90 Kauper, McGovern, Sherman 2012; 53 Shibagaki, Okamoto, Katsuta 2015; 139 Wong, Dresner, Forooghian 2013; 54 van Lookeren Campagne, LeCouter, Yaspan 2014; 232 Fritsche, Chen, Schu 2013; 45 Holz, Sadda, Busbee 2018; 136 Schwartz, Regillo, Lam 2015; 385 Ding, Patel, Chan 2009; 28 Szeto 2014; 171 WoldeMussie, Ruiz, Wijono 2001; 42 Sadda, Guymer, Holz 2018; 125 Kashani, Lebkowski, Rahhal 2018; 10 Zeng, Whitmore, Sohn 2016; 238 Kumar-Singh 2019; 184 Hillmen, Young, Schubert 2006; 355 2022021802300768000_106.3.297.10 2022021802300768000_106.3.297.54 2022021802300768000_106.3.297.3 2022021802300768000_106.3.297.53 Donello (2022021802300768000_106.3.297.71) 2001; 296 2022021802300768000_106.3.297.4 2022021802300768000_106.3.297.56 2022021802300768000_106.3.297.5 2022021802300768000_106.3.297.11 Liao (2022021802300768000_106.3.297.55) 2020; 127 2022021802300768000_106.3.297.50 2022021802300768000_106.3.297.51 2022021802300768000_106.3.297.90 2022021802300768000_106.3.297.91 2022021802300768000_106.3.297.6 2022021802300768000_106.3.297.7 2022021802300768000_106.3.297.8 2022021802300768000_106.3.297.9 Lawson (2022021802300768000_106.3.297.61) 2016; 854 Yoles (2022021802300768000_106.3.297.72) 1999; 40 2022021802300768000_106.3.297.18 2022021802300768000_106.3.297.19 2022021802300768000_106.3.297.14 2022021802300768000_106.3.297.13 Rammes (2022021802300768000_106.3.297.33) 2015; 92 2022021802300768000_106.3.297.57 Flaxman (2022021802300768000_106.3.297.1) 2017; 5 2022021802300768000_106.3.297.16 2022021802300768000_106.3.297.15 2022021802300768000_106.3.297.59 2022021802300768000_106.3.297.43 2022021802300768000_106.3.297.87 2022021802300768000_106.3.297.42 Cho (2022021802300768000_106.3.297.12) 2001; 73 2022021802300768000_106.3.297.45 2022021802300768000_106.3.297.89 2022021802300768000_106.3.297.44 Cashman (2022021802300768000_106.3.297.83) 2015; 17 2022021802300768000_106.3.297.88 2022021802300768000_106.3.297.82 2022021802300768000_106.3.297.41 Jaffe (2022021802300768000_106.3.297.52) 2020; S0161-6420 2022021802300768000_106.3.297.85 2022021802300768000_106.3.297.40 2022021802300768000_106.3.297.84 Rosenfeld (2022021802300768000_106.3.297.34) 2018; 2 2022021802300768000_106.3.297.80 Shibagaki (2022021802300768000_106.3.297.63) 2015; 139 Chirco (2022021802300768000_106.3.297.20) 2016; 146 Kumar-Singh (2022021802300768000_106.3.297.78) 2019; 184 2022021802300768000_106.3.297.47 2022021802300768000_106.3.297.46 2022021802300768000_106.3.297.48 2022021802300768000_106.3.297.32 2022021802300768000_106.3.297.76 2022021802300768000_106.3.297.31 WoldeMussie (2022021802300768000_106.3.297.73) 2001; 42 Kuppermann (2022021802300768000_106.3.297.75) 2021; 41 2022021802300768000_106.3.297.77 Lafuente (2022021802300768000_106.3.297.70) 2001; 42 2022021802300768000_106.3.297.74 Guymer (2022021802300768000_106.3.297.92) 2019; 126 Schwartz (2022021802300768000_106.3.297.86) 2015; 385 Wong (2022021802300768000_106.3.297.2) 2014; 2 2022021802300768000_106.3.297.39 2022021802300768000_106.3.297.36 2022021802300768000_106.3.297.35 Holz (2022021802300768000_106.3.297.49) 2018; 136 2022021802300768000_106.3.297.79 2022021802300768000_106.3.297.38 2022021802300768000_106.3.297.37 2022021802300768000_106.3.297.64 2022021802300768000_106.3.297.23 2022021802300768000_106.3.297.67 2022021802300768000_106.3.297.22 2022021802300768000_106.3.297.66 Lachmann (2022021802300768000_106.3.297.81) 2019; 224 2022021802300768000_106.3.297.60 Zeng (2022021802300768000_106.3.297.21) 2016; 238 2022021802300768000_106.3.297.62 Pardue (2022021802300768000_106.3.297.65) 2018; 65 Evans (2022021802300768000_106.3.297.30) 2017; 7 Shaw (2022021802300768000_106.3.297.58) 2020; 29 Chew (2022021802300768000_106.3.297.29) 2014; 132 Ebrahimi (2022021802300768000_106.3.297.17) 2011; 2011 2022021802300768000_106.3.297.28 2022021802300768000_106.3.297.25 2022021802300768000_106.3.297.69 2022021802300768000_106.3.297.24 2022021802300768000_106.3.297.68 2022021802300768000_106.3.297.27 2022021802300768000_106.3.297.26 |
| References_xml | – volume: 2011 start-page: 1 year: 2011 ident: R17 article-title: Lipids, lipoproteins, and age-related macular degeneration publication-title: J Lipids doi: 10.1155/2011/802059 – volume: 40 start-page: 65 year: 1999 ident: R72 article-title: Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration publication-title: Invest Ophthalmol Vis Sci – volume: 132 start-page: 142 year: 2014 ident: R29 article-title: Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2013.7376 – volume: 854 start-page: 431 year: 2016 ident: R61 article-title: Tauroursodeoxycholic acid protects retinal function and structure in RD1 mice publication-title: Adv Exp Med Biol doi: 10.1007/978-3-319-17121-0_57 – volume: 171 start-page: 2029 year: 2014 ident: R88 article-title: First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics publication-title: Br J Pharmacol doi: 10.1111/bph.12461 – volume: 125 start-page: 537 year: 2018 ident: R8 article-title: Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2017.09.028 – volume: 41 start-page: 144 year: 2021 ident: R75 article-title: Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0000000000002789 – volume: 6 year: 2011 ident: R79 article-title: A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration publication-title: PLoS One doi: 10.1371/journal.pone.0019078 – volume: 92 start-page: 158 year: 2015 ident: R36 article-title: MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD) publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.12.038 – volume: 42 start-page: 2074 year: 2001 ident: R70 article-title: Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death publication-title: Invest Ophthalmol Vis Sci – volume: 121 start-page: 693 year: 2014 ident: R46 article-title: Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the complete study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.09.044 – volume: 116 start-page: 144 year: 2011 ident: R60 article-title: Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration publication-title: J Neurochem doi: 10.1111/j.1471-4159.2010.07092.x – volume: 134 start-page: 411 year: 2002 ident: R15 article-title: A role for local inflammation in the formation of drusen in the aging eye publication-title: Am J Ophthalmol doi: 10.1016/s0002-9394(02)01624-0 – volume: 224 start-page: 511 year: 2019 ident: R81 article-title: The story of complement factor I publication-title: Immunobiology doi: 10.1016/j.imbio.2019.05.003 – volume: 309 start-page: 2005 year: 2013 ident: R28 article-title: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2013.4997 – volume: 42 start-page: 2849 year: 2001 ident: R73 article-title: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension publication-title: Invest Ophthalmol Vis Sci – volume: 147 start-page: 103 year: 1998 ident: R13 article-title: Relation of smoking to the incidence of age-related maculopathy. The Beaver dam eye study publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a009421 – volume: 128 start-page: 349 year: 2010 ident: R19 article-title: Complement, age-related macular degeneration and a vision of the future publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2010.18 – volume: 238 start-page: 446 year: 2016 ident: R21 article-title: Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration publication-title: J Pathol doi: 10.1002/path.4669 – volume: 60 year: 2019 ident: R74 article-title: Cyto-/neuro-protective effects of brimonidine drug delivery system (DDS) in a nonhuman primate progressive retinal degeneration model of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) publication-title: Invest Ophthalmol Vis Sci – volume: 120 start-page: 844 year: 2013 ident: R9 article-title: Clinical classification of age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.10.036 – volume: 98 start-page: 1128 year: 1991 ident: R6 article-title: The Wisconsin age-related maculopathy grading system publication-title: Ophthalmology doi: 10.1016/S0161-6420(91)32186-9 – volume: 31 start-page: E1445 year: 2010 ident: R45 article-title: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome publication-title: Hum Mutat doi: 10.1002/humu.21256 – volume: 5 start-page: e1221 year: 2017 ident: R1 article-title: Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30393-5 – volume: 151 start-page: 671 year: 2011 ident: R68 article-title: A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2010.09.026 – volume: 92 start-page: 170 year: 2015 ident: R33 article-title: MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.12.037 – volume: 179 start-page: 67 year: 2017 ident: R85 article-title: Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2017.04.006 – volume: 7 start-page: CD000254 year: 2017 ident: R30 article-title: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD000254.pub4 – volume: 24 start-page: 80 year: 2008 ident: R69 article-title: A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies publication-title: J Ocul Pharmacol Ther doi: 10.1089/jop.2007.0022 – volume: 73 start-page: 209 year: 2001 ident: R12 article-title: Prospective study of dietary fat and the risk of age-related macular degeneration publication-title: Am J Clin Nutr doi: 10.1093/ajcn/73.2.209 – volume: 91 start-page: 111 year: 2010 ident: R31 article-title: Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats publication-title: Exp Eye Res doi: 10.1016/j.exer.2010.04.012 – volume: 287 start-page: 12886 year: 2012 ident: R48 article-title: Inhibiting alternative pathway complement activation by targeting the factor D exosite publication-title: J Biol Chem doi: 10.1074/jbc.M112.345082 – volume: 286 start-page: 7966 year: 2011 ident: R42 article-title: C20-D3-vitamin a slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease publication-title: J Biol Chem doi: 10.1074/jbc.M110.178657 – volume: 61 year: 2020 ident: R82 article-title: GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD) publication-title: Invest Ophthalmol Vis Sci – volume: 184 start-page: 266 year: 2019 ident: R78 article-title: The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials publication-title: Exp Eye Res doi: 10.1016/j.exer.2019.05.006 – volume: 35 start-page: S18 year: 2003 ident: R50 article-title: The rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation publication-title: Transplant Proc doi: 10.1016/S0041-1345(03)00356-7 – volume: 49 start-page: 2148 year: 2008 ident: R62 article-title: Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-1012 – volume: 146 start-page: 393 year: 2016 ident: R20 article-title: Selective accumulation of the complement membrane attack complex in aging choriocapillaris publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.09.003 – volume: 33 start-page: 498 year: 2013 ident: R41 article-title: Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0b013e318265801d – volume: 28 start-page: 1 year: 2009 ident: R25 article-title: Molecular pathology of age-related macular degeneration publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2008.10.001 – volume: 105 start-page: 151 year: 2021 ident: R5 article-title: Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2020-316195 – volume: 114 start-page: 1518 year: 1996 ident: R14 article-title: Smoking and age-related maculopathy. the blue Mountains eye study publication-title: Arch Ophthalmol doi: 10.1001/archopht.1996.01100140716016 – volume: 19 year: 2019 ident: R4 article-title: Incremental economic burden associated with exudative age-related macular degeneration: a population-based study publication-title: BMC Health Serv Res doi: 10.1186/s12913-019-4666-0 – volume: 31 start-page: 136 year: 2012 ident: R64 article-title: Cntf and retina publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2011.11.005 – volume: 90 start-page: 1601 year: 2009 ident: R27 article-title: {omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2009.27594 – volume: 25 start-page: 1089 year: 2007 ident: R84 article-title: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease publication-title: Stem Cells doi: 10.1634/stemcells.2006-0308erratum – volume: 93 start-page: 565 year: 2011 ident: R24 article-title: Elevated membrane attack complex in human choroid with high risk complement factor H genotypes publication-title: Exp Eye Res doi: 10.1016/j.exer.2011.06.015 – volume: 17 start-page: 229 year: 2015 ident: R83 article-title: Adenovirus-mediated delivery of factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age-related macular degeneration publication-title: J Gene Med doi: 10.1002/jgm.2865 – volume: 2 start-page: 1028 year: 2018 ident: R34 article-title: A randomized phase 2 study of an anti-amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2018.03.001 – volume: 2 start-page: e106 year: 2014 ident: R2 article-title: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70145-1 – volume: 39 start-page: 367 year: 1995 ident: R7 article-title: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International arm epidemiological study group publication-title: Surv Ophthalmol doi: 10.1016/s0039-6257(05)80092-x – volume: 54 start-page: 2941 year: 2013 ident: R51 article-title: Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11650 – volume: 53 start-page: 7484 year: 2012 ident: R67 article-title: Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.12-9970 – volume: 232 start-page: 151 year: 2014 ident: R18 article-title: Mechanisms of age-related macular degeneration and therapeutic opportunities publication-title: J Pathol doi: 10.1002/path.4266 – volume: 136 start-page: 61666 year: 2018 ident: R49 article-title: Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.1544 – volume: 127 start-page: 186 year: 2020 ident: R55 article-title: Complement C3 inhibitor Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2019.07.011 – volume: 29 start-page: 696 year: 2015 ident: R91 article-title: Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage publication-title: Faseb J doi: 10.1096/fj.14-262444 – volume: 351 start-page: 527 year: 2014 ident: R47 article-title: Complement inhibition in cynomolgus monkeys by anti-factor D antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.114.215921 – volume: 126 start-page: 829 year: 2019 ident: R92 article-title: Subthreshold nanosecond laser intervention in age-related macular degeneration: the lead randomized controlled clinical trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2018.09.015 – volume: 52 start-page: 1606 year: 2011 ident: R23 article-title: Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6476 – volume: 51 start-page: 6131 year: 2010 ident: R32 article-title: Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-5637 – volume: 60 start-page: 201 year: 2017 ident: R11 article-title: The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2017.03.002 – volume: 385 start-page: 509 year: 2015 ident: R86 article-title: Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies publication-title: Lancet doi: 10.1016/S0140-6736(14)61376-3 – volume: 125 start-page: 1556 year: 2018 ident: R39 article-title: Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2018.03.059 – volume: 28 start-page: 63 year: 2009 ident: R16 article-title: Age-related maculopathy - linking aetiology and pathophysiological changes to the ischaemia hypothesis publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2008.11.004 – volume: 65 start-page: 50 year: 2018 ident: R65 article-title: Neuroprotective strategies for retinal disease publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2018.02.002 – volume: 46 start-page: 4393 year: 2005 ident: R40 article-title: Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.05-0820 – volume: 286 start-page: 7958 year: 2011 ident: R43 article-title: Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents publication-title: J Biol Chem doi: 10.1074/jbc.M110.178640 – volume: 57 year: 2016 ident: R89 article-title: Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the Mito-Reparative drug MTP-131 publication-title: Invest Ophthalmol Vis Scie – volume: 296 start-page: 216 year: 2001 ident: R71 article-title: alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia publication-title: J Pharmacol Exp Ther – volume: 355 start-page: 1233 year: 2006 ident: R44 article-title: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/NEJMoa061648 – volume: 139 start-page: 64 year: 2015 ident: R63 article-title: Beneficial protective effect of pramipexole on light-induced retinal damage in mice publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.07.007 – volume: 26 start-page: 57 year: 2008 ident: R3 article-title: Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study publication-title: Pharmacoeconomics doi: 10.2165/00019053-200826010-00006 – volume: 10 year: 2018 ident: R87 article-title: A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aao4097 – volume: 61 year: 2020 ident: R53 article-title: Avacincaptad pegol, a novel C5 inhibitor, significantly reduces the mean rate of geographic atrophy growth in a pivotal clinical trial publication-title: Invest Ophthalmol Vis Sci – volume: 45 start-page: 433 year: 2013 ident: R26 article-title: Seven new loci associated with age-related macular degeneration publication-title: Nat Genet doi: 10.1038/ng.2578 – volume: 29 start-page: 547 year: 2020 ident: R58 article-title: Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2020.1763953 – volume: 26 start-page: R45 year: 2017 ident: R10 article-title: Genetics of age-related macular degeneration (AMD) publication-title: Hum Mol Genet doi: 10.1093/hmg/ddx228 – volume: 45 start-page: 1 year: 2015 ident: R22 article-title: Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2014.11.005 – volume: S0161-6420 start-page: 30845 year: 2020 ident: R52 article-title: C5 inhibitor Avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2020.08.027 – volume: 103 start-page: 3896 year: 2006 ident: R66 article-title: Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0600236103 – volume: 351 start-page: 527 year: 2014 article-title: Complement inhibition in cynomolgus monkeys by anti-factor D antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.114.215921 – volume: 139 start-page: 64 year: 2015 article-title: Beneficial protective effect of pramipexole on light-induced retinal damage in mice publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.07.007 – volume: 309 start-page: 2005 year: 2013 article-title: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2013.4997 – volume: 126 start-page: 829 year: 2019 article-title: Subthreshold nanosecond laser intervention in age-related macular degeneration: the lead randomized controlled clinical trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2018.09.015 – volume: 105 start-page: 151 year: 2021 article-title: Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2020-316195 – volume: 134 start-page: 411 year: 2002 article-title: A role for local inflammation in the formation of drusen in the aging eye publication-title: Am J Ophthalmol doi: 10.1016/s0002-9394(02)01624-0 – volume: 26 start-page: R45 year: 2017 article-title: Genetics of age-related macular degeneration (AMD) publication-title: Hum Mol Genet doi: 10.1093/hmg/ddx228 – volume: 854 start-page: 431 year: 2016 article-title: Tauroursodeoxycholic acid protects retinal function and structure in RD1 mice publication-title: Adv Exp Med Biol doi: 10.1007/978-3-319-17121-0_57 – volume: 184 start-page: 266 year: 2019 article-title: The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials publication-title: Exp Eye Res doi: 10.1016/j.exer.2019.05.006 – volume: 53 start-page: 7484 year: 2012 article-title: Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.12-9970 – volume: 19 year: 2019 article-title: Incremental economic burden associated with exudative age-related macular degeneration: a population-based study publication-title: BMC Health Serv Res doi: 10.1186/s12913-019-4666-0 – volume: 52 start-page: 1606 year: 2011 article-title: Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6476 – volume: 45 start-page: 433 year: 2013 article-title: Seven new loci associated with age-related macular degeneration publication-title: Nat Genet doi: 10.1038/ng.2578 – volume: 355 start-page: 1233 year: 2006 article-title: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/NEJMoa061648 – volume: 286 start-page: 7958 year: 2011 article-title: Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents publication-title: J Biol Chem doi: 10.1074/jbc.M110.178640 – volume: 171 start-page: 2029 year: 2014 article-title: First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics publication-title: Br J Pharmacol doi: 10.1111/bph.12461 – volume: 35 start-page: S18 year: 2003 article-title: The rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation publication-title: Transplant Proc doi: 10.1016/S0041-1345(03)00356-7 – volume: 7 start-page: CD000254 year: 2017 article-title: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD000254.pub4 – volume: 65 start-page: 50 year: 2018 article-title: Neuroprotective strategies for retinal disease publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2018.02.002 – volume: 40 start-page: 65 year: 1999 article-title: Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration publication-title: Invest Ophthalmol Vis Sci – volume: 120 start-page: 844 year: 2013 article-title: Clinical classification of age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.10.036 – volume: 49 start-page: 2148 year: 2008 article-title: Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-1012 – volume: 147 start-page: 103 year: 1998 article-title: Relation of smoking to the incidence of age-related maculopathy. The Beaver dam eye study publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a009421 – volume: 2 start-page: 1028 year: 2018 article-title: A randomized phase 2 study of an anti-amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2018.03.001 – volume: 286 start-page: 7966 year: 2011 article-title: C20-D3-vitamin a slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease publication-title: J Biol Chem doi: 10.1074/jbc.M110.178657 – volume: 54 start-page: 2941 year: 2013 article-title: Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11650 – volume: 6 year: 2011 article-title: A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration publication-title: PLoS One doi: 10.1371/journal.pone.0019078 – volume: 2 start-page: e106 year: 2014 article-title: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70145-1 – volume: 45 start-page: 1 year: 2015 article-title: Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2014.11.005 – volume: 179 start-page: 67 year: 2017 article-title: Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2017.04.006 – volume: 125 start-page: 537 year: 2018 article-title: Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2017.09.028 – volume: 92 start-page: 158 year: 2015 article-title: MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD) publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.12.038 – volume: 125 start-page: 1556 year: 2018 article-title: Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2018.03.059 – volume: 103 start-page: 3896 year: 2006 article-title: Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0600236103 – volume: 98 start-page: 1128 year: 1991 article-title: The Wisconsin age-related maculopathy grading system publication-title: Ophthalmology doi: 10.1016/S0161-6420(91)32186-9 – volume: 61 year: 2020 article-title: Avacincaptad pegol, a novel C5 inhibitor, significantly reduces the mean rate of geographic atrophy growth in a pivotal clinical trial publication-title: Invest Ophthalmol Vis Sci – volume: 61 year: 2020 article-title: GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD) publication-title: Invest Ophthalmol Vis Sci – volume: 28 start-page: 1 year: 2009 article-title: Molecular pathology of age-related macular degeneration publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2008.10.001 – volume: 60 year: 2019 article-title: Cyto-/neuro-protective effects of brimonidine drug delivery system (DDS) in a nonhuman primate progressive retinal degeneration model of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) publication-title: Invest Ophthalmol Vis Sci – volume: 121 start-page: 693 year: 2014 article-title: Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the complete study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.09.044 – volume: 92 start-page: 170 year: 2015 article-title: MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.12.037 – volume: 151 start-page: 671 year: 2011 article-title: A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2010.09.026 – volume: 232 start-page: 151 year: 2014 article-title: Mechanisms of age-related macular degeneration and therapeutic opportunities publication-title: J Pathol doi: 10.1002/path.4266 – volume: 238 start-page: 446 year: 2016 article-title: Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration publication-title: J Pathol doi: 10.1002/path.4669 – volume: 93 start-page: 565 year: 2011 article-title: Elevated membrane attack complex in human choroid with high risk complement factor H genotypes publication-title: Exp Eye Res doi: 10.1016/j.exer.2011.06.015 – volume: 136 start-page: 61666 year: 2018 article-title: Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.1544 – volume: 24 start-page: 80 year: 2008 article-title: A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies publication-title: J Ocul Pharmacol Ther doi: 10.1089/jop.2007.0022 – volume: 132 start-page: 142 year: 2014 article-title: Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2013.7376 – volume: 5 start-page: e1221 year: 2017 article-title: Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30393-5 – volume: 42 start-page: 2849 year: 2001 article-title: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension publication-title: Invest Ophthalmol Vis Sci – volume: 29 start-page: 696 year: 2015 article-title: Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage publication-title: Faseb J doi: 10.1096/fj.14-262444 – volume: 51 start-page: 6131 year: 2010 article-title: Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-5637 – volume: 25 start-page: 1089 year: 2007 article-title: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease publication-title: Stem Cells doi: 10.1634/stemcells.2006-0308erratum – volume: S0161-6420 start-page: 30845 year: 2020 article-title: C5 inhibitor Avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2020.08.027 – volume: 224 start-page: 511 year: 2019 article-title: The story of complement factor I publication-title: Immunobiology doi: 10.1016/j.imbio.2019.05.003 – volume: 73 start-page: 209 year: 2001 article-title: Prospective study of dietary fat and the risk of age-related macular degeneration publication-title: Am J Clin Nutr doi: 10.1093/ajcn/73.2.209 – volume: 2011 start-page: 1 year: 2011 article-title: Lipids, lipoproteins, and age-related macular degeneration publication-title: J Lipids doi: 10.1155/2011/802059 – volume: 385 start-page: 509 year: 2015 article-title: Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies publication-title: Lancet doi: 10.1016/S0140-6736(14)61376-3 – volume: 10 year: 2018 article-title: A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aao4097 – volume: 127 start-page: 186 year: 2020 article-title: Complement C3 inhibitor Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2019.07.011 – volume: 91 start-page: 111 year: 2010 article-title: Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats publication-title: Exp Eye Res doi: 10.1016/j.exer.2010.04.012 – volume: 146 start-page: 393 year: 2016 article-title: Selective accumulation of the complement membrane attack complex in aging choriocapillaris publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.09.003 – volume: 33 start-page: 498 year: 2013 article-title: Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0b013e318265801d – volume: 17 start-page: 229 year: 2015 article-title: Adenovirus-mediated delivery of factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age-related macular degeneration publication-title: J Gene Med doi: 10.1002/jgm.2865 – volume: 39 start-page: 367 year: 1995 article-title: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International arm epidemiological study group publication-title: Surv Ophthalmol doi: 10.1016/s0039-6257(05)80092-x – volume: 46 start-page: 4393 year: 2005 article-title: Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.05-0820 – volume: 287 start-page: 12886 year: 2012 article-title: Inhibiting alternative pathway complement activation by targeting the factor D exosite publication-title: J Biol Chem doi: 10.1074/jbc.M112.345082 – volume: 116 start-page: 144 year: 2011 article-title: Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration publication-title: J Neurochem doi: 10.1111/j.1471-4159.2010.07092.x – volume: 90 start-page: 1601 year: 2009 article-title: {omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2009.27594 – volume: 31 start-page: 136 year: 2012 article-title: Cntf and retina publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2011.11.005 – volume: 28 start-page: 63 year: 2009 article-title: Age-related maculopathy - linking aetiology and pathophysiological changes to the ischaemia hypothesis publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2008.11.004 – volume: 128 start-page: 349 year: 2010 article-title: Complement, age-related macular degeneration and a vision of the future publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2010.18 – volume: 26 start-page: 57 year: 2008 article-title: Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study publication-title: Pharmacoeconomics doi: 10.2165/00019053-200826010-00006 – volume: 296 start-page: 216 year: 2001 article-title: alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia publication-title: J Pharmacol Exp Ther – volume: 41 start-page: 144 year: 2021 article-title: Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0000000000002789 – volume: 60 start-page: 201 year: 2017 article-title: The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2017.03.002 – volume: 31 start-page: E1445 year: 2010 article-title: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome publication-title: Hum Mutat doi: 10.1002/humu.21256 – volume: 29 start-page: 547 year: 2020 article-title: Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2020.1763953 – volume: 42 start-page: 2074 year: 2001 article-title: Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death publication-title: Invest Ophthalmol Vis Sci – volume: 57 year: 2016 article-title: Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the Mito-Reparative drug MTP-131 publication-title: Invest Ophthalmol Vis Scie – volume: 114 start-page: 1518 year: 1996 article-title: Smoking and age-related maculopathy. the blue Mountains eye study publication-title: Arch Ophthalmol doi: 10.1001/archopht.1996.01100140716016 – volume: 238 start-page: 446 year: 2016 ident: 2022021802300768000_106.3.297.21 article-title: Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration publication-title: J Pathol doi: 10.1002/path.4669 – ident: 2022021802300768000_106.3.297.44 doi: 10.1056/NEJMoa061648 – ident: 2022021802300768000_106.3.297.40 doi: 10.1167/iovs.05-0820 – ident: 2022021802300768000_106.3.297.5 doi: 10.1136/bjophthalmol-2020-316195 – ident: 2022021802300768000_106.3.297.38 – ident: 2022021802300768000_106.3.297.54 – volume: 65 start-page: 50 year: 2018 ident: 2022021802300768000_106.3.297.65 article-title: Neuroprotective strategies for retinal disease publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2018.02.002 – ident: 2022021802300768000_106.3.297.28 doi: 10.1001/jama.2013.4997 – ident: 2022021802300768000_106.3.297.57 – volume: 132 start-page: 142 year: 2014 ident: 2022021802300768000_106.3.297.29 article-title: Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2013.7376 – volume: S0161-6420 start-page: 30845 year: 2020 ident: 2022021802300768000_106.3.297.52 article-title: C5 inhibitor Avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial publication-title: Ophthalmology – ident: 2022021802300768000_106.3.297.13 doi: 10.1093/oxfordjournals.aje.a009421 – ident: 2022021802300768000_106.3.297.7 doi: 10.1016/S0039-6257(05)80092-X – ident: 2022021802300768000_106.3.297.16 doi: 10.1016/j.preteyeres.2008.11.004 – ident: 2022021802300768000_106.3.297.69 doi: 10.1089/jop.2007.0022 – ident: 2022021802300768000_106.3.297.84 doi: 10.1634/stemcells.2006-0308. – volume: 42 start-page: 2074 year: 2001 ident: 2022021802300768000_106.3.297.70 article-title: Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death publication-title: Invest Ophthalmol Vis Sci – ident: 2022021802300768000_106.3.297.6 doi: 10.1016/S0161-6420(91)32186-9 – ident: 2022021802300768000_106.3.297.43 doi: 10.1074/jbc.M110.178640 – volume: 184 start-page: 266 year: 2019 ident: 2022021802300768000_106.3.297.78 article-title: The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials publication-title: Exp Eye Res doi: 10.1016/j.exer.2019.05.006 – ident: 2022021802300768000_106.3.297.89 – ident: 2022021802300768000_106.3.297.9 doi: 10.1016/j.ophtha.2012.10.036 – ident: 2022021802300768000_106.3.297.76 – ident: 2022021802300768000_106.3.297.37 – ident: 2022021802300768000_106.3.297.41 doi: 10.1097/IAE.0b013e318265801d – ident: 2022021802300768000_106.3.297.10 doi: 10.1093/hmg/ddx228 – volume: 29 start-page: 547 year: 2020 ident: 2022021802300768000_106.3.297.58 article-title: Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2020.1763953 – ident: 2022021802300768000_106.3.297.62 doi: 10.1167/iovs.07-1012 – volume: 127 start-page: 186 year: 2020 ident: 2022021802300768000_106.3.297.55 article-title: Complement C3 inhibitor Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2019.07.011 – volume: 136 start-page: 61666 year: 2018 ident: 2022021802300768000_106.3.297.49 article-title: Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.1544 – ident: 2022021802300768000_106.3.297.8 doi: 10.1016/j.ophtha.2017.09.028 – ident: 2022021802300768000_106.3.297.66 doi: 10.1073/pnas.0600236103 – ident: 2022021802300768000_106.3.297.82 – volume: 2 start-page: 1028 year: 2018 ident: 2022021802300768000_106.3.297.34 article-title: A randomized phase 2 study of an anti-amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2018.03.001 – ident: 2022021802300768000_106.3.297.47 doi: 10.1124/jpet.114.215921 – ident: 2022021802300768000_106.3.297.87 doi: 10.1126/scitranslmed.aao4097 – volume: 146 start-page: 393 year: 2016 ident: 2022021802300768000_106.3.297.20 article-title: Selective accumulation of the complement membrane attack complex in aging choriocapillaris publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.09.003 – volume: 7 start-page: CD000254 year: 2017 ident: 2022021802300768000_106.3.297.30 article-title: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration publication-title: Cochrane Database Syst Rev – volume: 5 start-page: e1221 year: 2017 ident: 2022021802300768000_106.3.297.1 article-title: Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30393-5 – ident: 2022021802300768000_106.3.297.36 doi: 10.1016/j.neuropharm.2014.12.038 – ident: 2022021802300768000_106.3.297.19 doi: 10.1001/archophthalmol.2010.18 – ident: 2022021802300768000_106.3.297.22 doi: 10.1016/j.preteyeres.2014.11.005 – ident: 2022021802300768000_106.3.297.26 doi: 10.1038/ng.2578 – ident: 2022021802300768000_106.3.297.88 doi: 10.1111/bph.12461 – volume: 2011 start-page: 1 year: 2011 ident: 2022021802300768000_106.3.297.17 article-title: Lipids, lipoproteins, and age-related macular degeneration publication-title: J Lipids doi: 10.1155/2011/802059 – ident: 2022021802300768000_106.3.297.24 doi: 10.1016/j.exer.2011.06.015 – ident: 2022021802300768000_106.3.297.25 doi: 10.1016/j.preteyeres.2008.10.001 – ident: 2022021802300768000_106.3.297.15 doi: 10.1016/S0002-9394(02)01624-0 – volume: 385 start-page: 509 year: 2015 ident: 2022021802300768000_106.3.297.86 article-title: Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies publication-title: Lancet doi: 10.1016/S0140-6736(14)61376-3 – ident: 2022021802300768000_106.3.297.23 doi: 10.1167/iovs.10-6476 – volume: 139 start-page: 64 year: 2015 ident: 2022021802300768000_106.3.297.63 article-title: Beneficial protective effect of pramipexole on light-induced retinal damage in mice publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.07.007 – ident: 2022021802300768000_106.3.297.90 – volume: 854 start-page: 431 year: 2016 ident: 2022021802300768000_106.3.297.61 article-title: Tauroursodeoxycholic acid protects retinal function and structure in RD1 mice publication-title: Adv Exp Med Biol doi: 10.1007/978-3-319-17121-0_57 – ident: 2022021802300768000_106.3.297.67 doi: 10.1167/iovs.12-9970 – volume: 42 start-page: 2849 year: 2001 ident: 2022021802300768000_106.3.297.73 article-title: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension publication-title: Invest Ophthalmol Vis Sci – ident: 2022021802300768000_106.3.297.46 doi: 10.1016/j.ophtha.2013.09.044 – ident: 2022021802300768000_106.3.297.51 doi: 10.1167/iovs.13-11650 – ident: 2022021802300768000_106.3.297.59 – ident: 2022021802300768000_106.3.297.27 doi: 10.3945/ajcn.2009.27594 – ident: 2022021802300768000_106.3.297.39 doi: 10.1016/j.ophtha.2018.03.059 – volume: 2 start-page: e106 year: 2014 ident: 2022021802300768000_106.3.297.2 article-title: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70145-1 – ident: 2022021802300768000_106.3.297.4 doi: 10.1186/s12913-019-4666-0 – ident: 2022021802300768000_106.3.297.68 doi: 10.1016/j.ajo.2010.09.026 – ident: 2022021802300768000_106.3.297.18 doi: 10.1002/path.4266 – volume: 41 start-page: 144 year: 2021 ident: 2022021802300768000_106.3.297.75 article-title: Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0000000000002789 – ident: 2022021802300768000_106.3.297.14 doi: 10.1001/archopht.1996.01100140716016 – ident: 2022021802300768000_106.3.297.45 doi: 10.1002/humu.21256 – ident: 2022021802300768000_106.3.297.74 – ident: 2022021802300768000_106.3.297.85 doi: 10.1016/j.ajo.2017.04.006 – volume: 73 start-page: 209 year: 2001 ident: 2022021802300768000_106.3.297.12 article-title: Prospective study of dietary fat and the risk of age-related macular degeneration publication-title: Am J Clin Nutr doi: 10.1093/ajcn/73.2.209 – volume: 92 start-page: 170 year: 2015 ident: 2022021802300768000_106.3.297.33 article-title: MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.12.037 – ident: 2022021802300768000_106.3.297.42 doi: 10.1074/jbc.M110.178657 – ident: 2022021802300768000_106.3.297.53 – ident: 2022021802300768000_106.3.297.79 doi: 10.1371/journal.pone.0019078 – ident: 2022021802300768000_106.3.297.32 doi: 10.1167/iovs.10-5637 – ident: 2022021802300768000_106.3.297.91 doi: 10.1096/fj.14-262444 – ident: 2022021802300768000_106.3.297.60 doi: 10.1111/j.1471-4159.2010.07092.x – volume: 296 start-page: 216 year: 2001 ident: 2022021802300768000_106.3.297.71 article-title: alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia publication-title: J Pharmacol Exp Ther – ident: 2022021802300768000_106.3.297.35 – ident: 2022021802300768000_106.3.297.50 doi: 10.1016/S0041-1345(03)00356-7 – ident: 2022021802300768000_106.3.297.56 – ident: 2022021802300768000_106.3.297.31 doi: 10.1016/j.exer.2010.04.012 – ident: 2022021802300768000_106.3.297.48 doi: 10.1074/jbc.M112.345082 – volume: 126 start-page: 829 year: 2019 ident: 2022021802300768000_106.3.297.92 article-title: Subthreshold nanosecond laser intervention in age-related macular degeneration: the lead randomized controlled clinical trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2018.09.015 – ident: 2022021802300768000_106.3.297.80 – volume: 224 start-page: 511 year: 2019 ident: 2022021802300768000_106.3.297.81 article-title: The story of complement factor I publication-title: Immunobiology doi: 10.1016/j.imbio.2019.05.003 – ident: 2022021802300768000_106.3.297.77 – ident: 2022021802300768000_106.3.297.3 doi: 10.2165/00019053-200826010-00006 – ident: 2022021802300768000_106.3.297.64 doi: 10.1016/j.preteyeres.2011.11.005 – ident: 2022021802300768000_106.3.297.11 doi: 10.1016/j.preteyeres.2017.03.002 – volume: 17 start-page: 229 year: 2015 ident: 2022021802300768000_106.3.297.83 article-title: Adenovirus-mediated delivery of factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age-related macular degeneration publication-title: J Gene Med doi: 10.1002/jgm.2865 – volume: 40 start-page: 65 year: 1999 ident: 2022021802300768000_106.3.297.72 article-title: Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration publication-title: Invest Ophthalmol Vis Sci |
| SSID | ssj0002617 |
| Score | 2.6619859 |
| SecondaryResourceType | review_article |
| Snippet | Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of... |
| SourceID | pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 297 |
| SubjectTerms | angiogenesis Angiogenesis Inhibitors - therapeutic use Antioxidants Clinical trials degeneration Fatty acids Genes genetics Geographic Atrophy - therapy GLP-1 receptor agonists Health risk assessment Humans Lasers macula Macular degeneration Older people Oxidative stress Pathogenesis Pharmaceuticals R&D Research & development retina Review Vascular endothelial growth factor Vascular Endothelial Growth Factor A - genetics Visual Acuity Wet Macular Degeneration - drug therapy |
| Title | Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions |
| URI | https://bjo.bmj.com/content/106/3/297.full https://bjo.bmj.com/content/early/2021/03/19/bjophthalmol-2020-318452.full https://www.ncbi.nlm.nih.gov/pubmed/33741584 https://www.proquest.com/docview/2630437931 https://www.proquest.com/docview/2503448304 https://pubmed.ncbi.nlm.nih.gov/PMC8867261 |
| Volume | 106 |
| WOSCitedRecordID | wos000726872800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-2079 dateEnd: 20250609 omitProxy: false ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: 7X7 dateStart: 19220101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1468-2079 dateEnd: 20250609 omitProxy: false ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: BENPR dateStart: 19220101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxQxEA-2FfHF-lU9W0sEHxu62ewmWV9ES4svHkUq3NuST6_lbve8vQr-92ayH71TKAe-7EsmJMtMkt8kM_ND6H2qrHZeKxJ8A0EyLYEN0CTEMx3mHRCKkTqSTYjxWE4mxWV34dZ0YZX9nhg3alsbuCM_TTmDMjwFox8XPwmwRsHrakehsYP2gDYb7FxMBocrVhtv4a8gNECbPpKH8VN9Uy-mq6mazetZsJQ2jTiD9KMdPb_ZPKT-QZ5_B1CunUgX-__7L0_Rkw6L4k-t8TxDD1z1HD362r22v0D1VR-F3uCAbbFd_sZh-yEx_8VZPFcxiBVb9yMWrwYdf8BrGV0YuOrDvE5wn4CJI0tIg1VlcVvOBLeHKlj_S_T94vzq7AvpCBqI5glbESocL6S0GXW-AB4foRKXydxr6gB35ImjiRWc-6RwuS6Ce-K5kY6mqfOGW3aAdqu6cq8RzgNsCdjBB7-YZUxlqnBC-FxkJjXMGjpCJOil7BZYU0bfhfFyXY8l6LFs9ThCJyC_aEt2bCEueoWXpiuODhwdsy160qHn9qMd9XZx90d3RjFC74bmsNjhBUdVrr4NMjlUaJRBcIRetSY4DMoYgEMZWsSGcQ4CUEh8s6W6nsaC4lJyEdbKm_undYgep5D7EQPwjtDuannr3qKH5tfqulkex5UXv_IY7X0-H19--wN4qDsc |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF61BQEXngUCBRYJbl3V9tq7aySEEFC1ahtxCFJuxvswaZXYIUlB_VP8RmbWjyYgoVx64Lzj-JFvZr-xZ74h5FWUW-0KnTPIDSSLtcJpgCZgBddw3cBQjNJ-2ITs99VwmH7eIL_aXhgsq2xjog_UtjL4jnwvEhxleFIevpt-Zzg1Cr-utiM0algcuYufkLLN3x5-hP_3dRTtfxp8OGDNVAGmRcAXLJROpErZOHRFisNnZB64WCWFDh1ulkngwsBKIYogdYlOgVMXwigXRpErjLAcfneTXIM4LjHZk8MuwfPq5jXdliwEKtVWDnGxp8-q6WgxyseTagzIrNuWY2x32tSTs9VN8S-m-2fB5tIOuH_nf3t2d8nthmvT97Vz3CMbrrxPbpw01QQPSDVoq-znFLg7tbMLCuGV-f4eZ-kk90W61LpvXpwbMfyGLnWs0Ry2CngOu7RtMKV-Csqc5qWltVwLrUkDevc2-XIlt_uQbJVV6R4TmgAtA25UQN7PY57HeeqkLBIZm8hwa8IeYYCDrAkg88znZlxky7jJEDdZjZse2UX7aS1Jsoa5bAGWmUb8HWeQjNc4MuyOXP9sOy0OL-_oEoQ98rJbhmCGX6jy0lXnYJOgAqUCwx55VEO-OynnSH4VrMgVZ-gMUCh9daU8HXnBdKWEBN988u_LekFuHgxOjrPjw_7RU3Irwj4XX2y4Q7YWs3P3jFw3Pxan89lz7_WUfL1qV_kNbmmTvw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB61Kap64Q0NFFgkuNWK7bV310gIAW1EVYgiVKTezNq7Jq0SOyQpqH-NX8eMX01AQrn0wHnH8SPfzHxrz3wD8MLXJrFZoh3cG0gnSBRNA0xdJ-MJXjcylFQl5bAJORio09NouAG_ml4YKqtsYmIZqE2R0jvyni84yfBE3OtldVnE8KD_ZvrdoQlS9KW1GadRQeTYXv7E7dv89dEB_tcvfb9_ePL-g1NPGHAS4fKF40krIqVM4NksokE0Urs2UGGWeJYSZ-hazzVSiMyNbJhEyK8zkSrr-b7NUmE4_u4mbEkkGUEHtt4dDoaf2zxAWucV-ZaOh8SqqSPiopecF9PRYqTHk2KMOK2amANqftpMJuerKfIv3vtn-eZSPuzf-p-f5G24WbNw9rZymzuwYfO7sP2prjO4B8VJU38_Z8jqmZldMgy8Ttn5Yw2b6LJ8lxn7rZTtJnS_Yku9bExjEsFnss-a1lNWzkeZM50bVgm5sIpOkN_fhy_XcrsPoJMXud0FFiJhQ9aUhT7nAdeBjqyUWSiD1E-5Sb0uOIiJuA4t87jctXERL2MoJgzFFYa6sE_200qsZA1z2YAtTmtZeJpOMl7jSK89cv2z7TWYvLqjK0B24Xm7jGGOvl3p3BYXaBOSNqVCwy48rODfnpRzosUKV-SKY7QGJKG-upKfjUopdaWERD999O_Legbb6CHxx6PB8WPY8akBpqxC3IPOYnZhn8CN9MfibD57WocABl-v21d-A_etnd8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatments+for+dry+age-related+macular+degeneration%3A+therapeutic+avenues%2C+clinical+trials+and+future+directions&rft.jtitle=British+journal+of+ophthalmology&rft.au=Cabral+de+Guimaraes%2C+Thales+Antonio&rft.au=Daich+Varela%2C+Malena&rft.au=Georgiou%2C+Michalis&rft.au=Michaelides%2C+Michel&rft.date=2022-03-01&rft.pub=BMJ+Publishing+Group&rft.issn=0007-1161&rft.eissn=1468-2079&rft.volume=106&rft.issue=3&rft.spage=297&rft.epage=304&rft_id=info:doi/10.1136%2Fbjophthalmol-2020-318452&rft_id=info%3Apmid%2F33741584&rft.externalDocID=PMC8867261 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1161&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1161&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1161&client=summon |